Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joanne E Tomassini

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Contributions to Nephrology|June 1, 2011
Lipid abnormalities in patients with chronic kidney diseaseWilliam F Keane, Joanne E Tomassini, David R Neff
Journal of Atherosclerosis and Thrombosis|October 26, 2012
Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosisWilliam F Keane, Joanne E Tomassini, David R Neff
Current Opinion in Lipidology|November 22, 2011
Intestinal sterol transporters and cholesterol absorption inhibitionHarry R Davis, Andrew M Tershakovec, Joanne E Tomassini, et al.
Expert Review of Cardiovascular Therapy|April 12, 2008
Ezetimibe: cholesterol lowering and beyondHarold E Bays, David Neff, Joanne E Tomassini, et al.
The American Journal of Cardiology|August 8, 2009
Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial)Scott M Grundy, Gloria Lena Vega, Joanne E Tomassini, et al.
The American Journal of Cardiology|May 14, 2011
Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial)Scott M Grundy, Gloria Lena Vega, Joanne E Tomassini, et al.
Future Cardiology|April 16, 2016
Statin combination therapy and cardiovascular risk reductionPeter P Toth, Michel Farnier, Joanne E Tomassini, et al.
Surgical Infections|March 27, 2007
Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adultsNicholas Namias, Joseph S Solomkin, Erin H Jensen, et al.
Atherosclerosis|December 3, 2014
Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysisBaishali M Ambegaonkar, Diane Tipping, Adam B Polis, et al.
Fundamental & Clinical Pharmacology|November 29, 2014
Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response modelHarold E Bays, Erluo Chen, Joanne E Tomassini, et al.
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Contributions to Nephrology|June 1, 2011
Lipid abnormalities in patients with chronic kidney diseaseWilliam F Keane, Joanne E Tomassini, David R Neff
Journal of Atherosclerosis and Thrombosis|October 26, 2012
Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosisWilliam F Keane, Joanne E Tomassini, David R Neff
Current Opinion in Lipidology|November 22, 2011
Intestinal sterol transporters and cholesterol absorption inhibitionHarry R Davis, Andrew M Tershakovec, Joanne E Tomassini, et al.
Expert Review of Cardiovascular Therapy|April 12, 2008
Ezetimibe: cholesterol lowering and beyondHarold E Bays, David Neff, Joanne E Tomassini, et al.
The American Journal of Cardiology|August 8, 2009
Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial)Scott M Grundy, Gloria Lena Vega, Joanne E Tomassini, et al.
The American Journal of Cardiology|May 14, 2011
Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial)Scott M Grundy, Gloria Lena Vega, Joanne E Tomassini, et al.
Future Cardiology|April 16, 2016
Statin combination therapy and cardiovascular risk reductionPeter P Toth, Michel Farnier, Joanne E Tomassini, et al.
Surgical Infections|March 27, 2007
Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adultsNicholas Namias, Joseph S Solomkin, Erin H Jensen, et al.
Atherosclerosis|December 3, 2014
Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysisBaishali M Ambegaonkar, Diane Tipping, Adam B Polis, et al.
Fundamental & Clinical Pharmacology|November 29, 2014
Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response modelHarold E Bays, Erluo Chen, Joanne E Tomassini, et al.
Pageof 8